Abstract The advent of immune Top Console Cap checkpoint inhibitors (ICIs) has significantly improved cancer treatment.With the increasing use of ICIs, ICI-related myocarditis has been recognized.However, an evidence-based therapeutic strategy has not been established because of the limited knowledge on ICI-related myocarditis.Here, we present four cases of ICI-related fulminant myocarditis (FM).
Three of the four cases resulted in fatal outcomes despite aggressive treatment with mechanical circulatory support and immunosuppressive therapy with corticosteroids.Given the poor prognosis of ICI-FM, the establishment King Adjustable Base of rapid and adequate therapeutic interventions on the basis of clinical and pathological evaluation is imperative.